Time from amyotrophic lateral sclerosis symptom onset to key disease milestones: analysis of data from a multinational cross-sectional survey

被引:2
|
作者
Gebrehiwet, Paulos [1 ,5 ]
Brekke, Johan [2 ]
Rudnicki, Stacy A. [3 ]
Mellor, Jennifer [4 ]
Wright, Jack [4 ]
Earl, Lucy [4 ]
Ball, Nathan [4 ]
Iqbal, Halima [4 ]
Thomas, Owen [4 ]
Castellano, Giorgio [4 ]
机构
[1] Cytokinetics Inc, Hlth Econ & Outcomes Res, South San Francisco, CA USA
[2] Cytokinetics Inc, Med Affairs, South San Francisco, CA USA
[3] Cytokinetics Inc, Clin Res, South San Francisco, CA USA
[4] Adelphi Real World, Real World Evidence, Bollington, England
[5] Cytokinetics Inc, Hlth Econ & Outcomes Res, 350 Oyster Point Blvd, South San Francisco, CA 94080 USA
关键词
Amyotrophic lateral sclerosis; clinical milestones; progression; multinational; ALS; BODY-MASS INDEX; STAGING SYSTEM; ALSFRS-R; PROGRESSION; SURVIVAL; DIAGNOSIS; EPIDEMIOLOGY; PROGNOSIS; PATIENT; RISK;
D O I
10.1080/21678421.2023.2297795
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
ObjectiveTo determine the average time from Amyotrophic Lateral Sclerosis (ALS) symptom onset to 11 pre-defined milestones, overall and according to ALS progression rate and geographic location.MethodsData were drawn from the Adelphi Real World ALS Disease-Specific ProgrammeTM, a point-in-time survey of neurologists caring for people living with ALS (pALS) conducted in France, Germany, Italy, Spain, the United Kingdom and the United States from 2020-2021. ALS progression rate was calculated using time since symptom onset and ALS Functional Rating Scale Revised score.ResultsSurvey results were available for N = 1003 pALS (progression rate for N = 867). Mean time from symptom onset was 3.8 months to first consultation, 8.0 months to diagnosis, 16.2 months to employment change (part-time/sick leave/retirement/unemployment), 17.5 months to use of a walking aid, 18.5 months to first occurrence of caregiver support, 22.8 months to use of a wheelchair, 24.6 months to use of a communication aid, 27.3 months to use of a respiratory aid, 28.6 months to use of gastrostomy feeding, 29.7 months to use of eye gaze technology and 30.3 months to entering a care facility. Multivariate analysis indicated significant effects of fast (versus slow) progression rate on time to reach all 11 milestones, as well as US (versus European) location, age, body mass index and bulbar onset (versus other) on time to reach milestones.ConclusionspALS rapidly reached clinical and disease-related milestones within 30 months from symptom onset. Milestones were reached significantly faster by pALS with fast versus slow progression. Geographic differences were observed.
引用
收藏
页码:345 / 357
页数:13
相关论文
共 50 条
  • [1] Pain at the onset of Amyotrophic Lateral Sclerosis: a cross-sectional study
    Taga, Arens
    Schito, Paride
    Trapasso, Maria Claudia
    Zinno, Lucia
    Pavesi, Giovanni
    CLINICAL NEUROLOGY AND NEUROSURGERY, 2019, 186
  • [2] Amyotrophic lateral sclerosis in seven provinces of Chinese mainland: A cross-sectional survey from 2015 to 2016
    Zhang, Jie
    Liu, Xiaoqing
    Liang, Huiting
    Xu, Shengyuan
    Wang, Xiaohua
    Xu, Renshi
    FRONTIERS IN AGING NEUROSCIENCE, 2022, 14
  • [3] A cross-sectional study of caregiver time use in amyotrophic lateral sclerosis
    Chio, A
    Piemonte, T
    Gauthier, A
    Vignola, A
    Calvo, A
    Ghiglione, P
    Terreni, AA
    Mutani, R
    NEUROLOGY, 2006, 66 (05) : A230 - A231
  • [4] Costs of illness in amyotrophic lateral sclerosis (ALS): a cross-sectional survey in Germany
    Schoenfelder, Erik
    Osmanovic, Alma
    Mueschen, Lars Hendrik
    Petri, Susanne
    Schreiber-Katz, Olivia
    ORPHANET JOURNAL OF RARE DISEASES, 2020, 15 (01)
  • [5] Costs of illness in amyotrophic lateral sclerosis (ALS): a cross-sectional survey in Germany
    Erik Schönfelder
    Alma Osmanovic
    Lars Hendrik Müschen
    Susanne Petri
    Olivia Schreiber-Katz
    Orphanet Journal of Rare Diseases, 15
  • [6] Latent class analysis of communication methods and devices among Japanese patients with amyotrophic lateral sclerosis: a cross-sectional survey
    Ishikawa, Takemasa
    Konishi, Kaoru
    SPEECH LANGUAGE AND HEARING, 2025, 28 (01)
  • [7] Modelling disease course in amyotrophic lateral Sclerosis: pseudo-longitudinal insights from cross-sectional health-related quality of life data
    Tino Prell
    Nayana Gaur
    Robert Steinbach
    Otto W. Witte
    Julian Grosskreutz
    Health and Quality of Life Outcomes, 18
  • [8] Modelling disease course in amyotrophic lateral Sclerosis: pseudo-longitudinal insights from cross-sectional health-related quality of life data
    Prell, Tino
    Gaur, Nayana
    Steinbach, Robert
    Witte, Otto W.
    Grosskreutz, Julian
    HEALTH AND QUALITY OF LIFE OUTCOMES, 2020, 18 (01)
  • [9] A Cross-Sectional, Quantitative Videofluoroscopic Analysis of Swallowing Physiology and Function in Individuals With Amyotrophic Lateral Sclerosis
    Waito, Ashley A.
    Plowman, Emily K.
    Barbon, Carly E. A.
    Peladeau-Pigeon, Melanie
    Tabor-Gray, Lauren
    Magennis, Kelby
    Robison, Raele
    Steele, Catriona M.
    JOURNAL OF SPEECH LANGUAGE AND HEARING RESEARCH, 2020, 63 (04): : 948 - 962
  • [10] Denervation findings on EMG in amyotrophic lateral sclerosis and correlation with prognostic milestones: Data from a retrospective study
    Fileccia, E.
    De Pasqua, S.
    Rizzo, G.
    Di Stasi, V
    Vacchiano, V.
    Avoni, P.
    Bartolomei, I
    Pastorelli, F.
    Plasmati, R.
    Donadio, V
    Salvi, F.
    Liguori, R.
    CLINICAL NEUROPHYSIOLOGY, 2020, 131 (08) : 2017 - 2022